Novo Nordisk A/S (NVO) Receives Tender Offer for 2M Shares

Novo Nordisk A/S (NYSE:NVO) is one of the best depressed stocks to buy in 2025. On August 4, the company confirmed it had received an unsolicited mini-tender offer from TRC Capital Investment Corporation.

The mini tender offer is for the purchase of up to 2 million American Depositary shares representing less than 0.045% of its total share capital. Novo Nordisk management remains neutral in the tender offer and has advised shareholders to exercise caution and consult financial advisors.

Given that the tender offer covers an immaterial stake, there will be no change in Novo Nordisk’s control or capital structure.

Novo Nordisk A/S (NYSE:NVO) is a healthcare company that develops and delivers innovative treatments for serious chronic diseases, with a particular emphasis on diabetes and obesity. It also develops treatments for rare blood and endocrine diseases, haemophilia, and growth disorders.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Medical AI Companies to Buy According to Analysts and 10 Best Rare Earth Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.